![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Antagonists of leukotriene D4 (LTD4) have shown clinical efficacy in the treatment of asthma while efficacy with antagonists of leukotriene B4 (LTB4) has yet to be demonstrated. The development of dual mediators possessing either histamine (H1), thromboxane (TXA2), or serine protease activity coupled with leukotriene antagonist activity offers a new direction of research, one which offers the greatest potential in discovering a superior agent for the treatment of allergic and inflammatory diseases.